Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse L
25/9 13:45
Company Announcement TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory ( R/R ) d iffuse large B-cell lymphoma ( DLBCL ) after two or more lines of systemic therapy Conditional marketing...